Akeso Initiates Phase III Trial of Cadonilimab Bispecific Antibody for PD-L1 Negative NSCLC
核心洞察
Akeso (搜索) has enrolled the first patient in a registrational Phase III trial comparing Cadonilimab, a PD-1 (搜索)/CTLA-4 (搜索) bispecific antibody, with Tislelizumab for first-line treatment of PD-L1 (搜索) negative non-small cell lung cancer.
The trial addresses a significant unmet medical need, as up to 48% of patients with driver gene-negative NSCLC have PD-L1 (搜索) negative expression and receive limited survival benefits from current treatments.
Previous studies have demonstrated that Cadonilimab exhibits a "high efficacy, low toxicity" profile and shows robust anti-tumor effects in patients with low or negative PD-L1 (搜索) expression across multiple cancer types.
Akeso (搜索) Inc. has announced the enrollment of the first patient in a registrational Phase III clinical study evaluating Cadonilimab, a PD-1 (搜索)/CTLA-4 (搜索) bispecific antibody, combined with chemotherapy versus Tislelizumab combined with chemotherapy for first-line treatment of patients with PD-L1 (搜索) negative non-small cell lung cancer (NSCLC). The trial (NCT05990127) specifically targets patients with PD-L1 tumor proportion score (TPS) less than 1%.
Addressing a Critical Treatment Gap
The study addresses a substantial unmet medical need in lung cancer treatment. Retrospective studies conducted worldwide and in China have revealed that PD-L1 (搜索) negative expression is observed in up to 48% of patients with driver gene-negative NSCLC. While immunotherapy combined with chemotherapy represents the first-line standard treatment for these patients, current treatment approaches provide limited survival benefits for the PD-L1 negative population.
According to Akeso (搜索), there exists a pressing clinical imperative for novel treatment modalities to enhance clinical outcomes for this patient population. The company notes that compared to PD-1 (搜索)/PD-L1 (搜索) monoclonal antibodies, PD-1 monoclonal antibody plus CTLA-4 (搜索) monoclonal antibody combined with chemotherapy provides greater benefits for the PD-L1 negative population.
Cadonilimab's Clinical Profile
Previous studies have demonstrated that Cadonilimab possesses a "high efficacy, low toxicity" profile and shows clinical efficacy in NSCLC patients with PD-L1 (搜索) negative expression. The bispecific antibody has shown promising results across multiple cancer types, with clinical studies demonstrating that combination therapy with Cadonilimab as first-line treatment for advanced gastric cancer and advanced cervical cancer provides significant survival benefits for all-comer patients, irrespective of their PD-L1 expression levels.
The therapeutic approach exhibits robust anti-tumor effects even in patients with low PD-L1 (搜索) expression or negative status, effectively addressing the limitations of current PD-1 (搜索)/PD-L1 monoclonal antibody immunotherapy. This mechanism has the potential to reshape the landscape of cancer treatment, according to the company.
Future Implications
Akeso (搜索) anticipates that Cadonilimab, in the treatment of PD-L1 (搜索) negative NSCLC population, will continue its unique advantages observed in gastric and cervical cancers. The company expects the therapy to become a new generation of efficient immunotherapy regimen for first-line treatment of advanced PD-L1 negative NSCLC patients.
The Phase III trial represents a critical step in potentially expanding treatment options for a significant subset of NSCLC patients who currently have limited therapeutic alternatives with meaningful survival benefits.